Calaspargase Pegol
Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizerprotein_peptidePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Carcinoma, Non-Small-Cell Lung (NSCLC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tuvonralimab Tang-Du Hospital | Phase 2 | CCC |
Same molecule, other indications
Calaspargase Pegol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →